-
Secukinumab, sold
under the
brand name
Cosentyx among others, is a
human IgG1κ
monoclonal antibody used for the
treatment of psoriasis,
ankylosing spondylitis...
- changes. In May 2023, the
European Commission (EC)
approved Cosentyx (
secukinumab) for
active moderate to
severe hidradenitis suppurativa in adults. Other...
- well as the IL-12/IL-23
inhibitor ustekinumab, the IL-17A
inhibitor secukinumab, and the IL-23
inhibitor risankizumab.
Biologics may
increase the risk...
-
demonstrated that
bimekizumab is
superior to not only
adalimumab but also
secukinumab and
ustekinumab for the
treatment of
plaque psoriasis. The
approval for...
- Woessner, Ralph; Pieber,
Thomas Rudolf; Cheng, Yi (November 23, 2015). "
Secukinumab distributes into
dermal interstitial fluid of
psoriasis patients as demonstrated...
- this
class target IL-17, an
important part of the
inflammatory system:
secukinumab and ixekizumab. They are
often considered in
cases where TNFi
drugs are...
- 2021-08-15.
Retrieved 2021-10-01. "Study:
Guselkumab More
Effective Than
Secukinumab in
Certain Subpo****tions".
Dermatology Times. 3
September 2021. Retrieved...
-
clinical trials which found that two anti-IL-17A antibodies,
namely secukinumab and
ixekizumab significantly benefit these patients. Th17
cells is also...
-
severe cases of psoriasis.
There is also some
evidence to
support use of
secukinumab, brodalumab, guselkumab, certolizumab, and ustekinumab. In general, anti-IL17...
-
antibodies available or
studied as
injector pens
include adalimumab,
secukinumab, and aliro****ab. CGRP
antagonists which are
monoclonal antibodies, used...
